GE Healthcare and Theragnostics have signed a global partnership to develop a new prostate-specific membrane antigen (PSMA) PET/CT imaging agent.
Theragnostics will lead the advancement of the tracer, called GalliProst, while GE will head commercial efforts toward preapproval of the agent and subsequent commercial and distribution activities, if and when regulatory clearance is achieved.
A phase II clinical study to evaluate the efficacy of GalliProst found that one-third of newly diagnosed prostate cancer patients -- more than 50% of whom had biochemically recurrent disease -- had their treatment plans modified as a result of the PSMA agent's findings. The change in patient management increased to 75% after radical radiotherapy.
